EGFR and non-small cell lung carcinoma: A total of 245 NSCLC patients harboring the L858R mutation with treatment and survival details were included in this analysis, of which 118 patients received EGFR TKIs as first-line therapy, whereas 127 patients received chemotherapy as first-line therapy.